Sarepta Therapeutics Inc. (SRPT)

133.31
NASDAQ : Health Technology
Prev Close 135.53
Day Low/High 133.25 / 136.30
52 Wk Low/High 35.26 / 176.50
Avg Volume 1.66M
Exchange NASDAQ
Shares Outstanding 65.53M
Market Cap 8.88B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bounce Opportunities Are the Name of the Game

Bounce Opportunities Are the Name of the Game

Everyone is a buyer of pullbacks when the market is going up but not so much when it's going down.

FAANG Stocks Are Being Nailed

FAANG Stocks Are Being Nailed

There are likely to be some good opportunities developing as this profit taking accelerates.

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta adds another 7% on top of nearly 40% gains on Tuesday following good results for a new gene therapy.

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results

But rival firm PTC Therapeutics tumbles nearly 31% on the news.

A Weak Close Is Going to Have a Significant Impact on Sentiment

A Weak Close Is Going to Have a Significant Impact on Sentiment

It is important for the bulls that the indices close near the highs of the day.

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.

These Pockets of Momentum Are Where the Action Is in This Market

These Pockets of Momentum Are Where the Action Is in This Market

Until that action dies it is difficult to be too bearish.

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

This underperformance is being caused by pockets of weakness in bigger-cap names.

Market Acting Like the Worst Is Over

Market Acting Like the Worst Is Over

Stocks are following through on Friday's rebound for now.

Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

--The program helps clinicians identify patients who may be eligible for Sarepta's clinical trials--

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

Rotational action is the main theme Wednesday and good opportunities are out there.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

Big Cap Tech Was the Play of the Day

Big Cap Tech Was the Play of the Day

With few catalysts for the markets, Tuesday's special election for a Pennsylvania congressional seat could set the tone this week.

There's Plenty of Positive Action But It's a Little Overheated

There's Plenty of Positive Action But It's a Little Overheated

I'll be watching for entry points to develop this afternoon.

There's No Big Rush for the Indices at this Point

There's No Big Rush for the Indices at this Point

The best way to deal with the struggling market is selective stock picking and good defense.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

It is important to note that watching for a reversal is much different than being short.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

TheStreet Quant Rating: D (Sell)